MR Antagonist and LSD1

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT04840342

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04840342
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04840342. Randomized; triple masking; primary purpose treatment. Start 2022-02-03 (actual); primary completion 2025-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MR Antagonist and LSD1
Condition
Hypertension
Condition
Mineralocorticoid Excess
Intervention (Drug)
Eplerenone
Intervention (Drug)
Amlodipine
Lead sponsor
Brigham and Women's Hospital (class: other)

Record details

Record id
cardio:ct-nct04840342
Content hash
d7d4ea2ffd234bb56c92e211b440baab726a873574db4f0a03bb1edf7ea51382